Urologia Internationalis · Nov 17, 2026
SGLT2 inhibitors: infection and bleeding risk after endourological prostate surgery
By Schwinger M, Lehmann A, Scheper V et al.
OBJECTIVE: To evaluate the perioperative safety of sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy in patients undergoing transurethral resection of the prostate (TUR-P) or holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia, with particular focus on infectious and bleeding-related complications. MATERIALS AND METHODS: This retrospective cohort study screened 258 patients undergoing TUR-P or HoLEP between January 2024 and March 2025. After exclusion of eight non-diabetic patients receiving SGLT2 inhibitors, 250 patients were included in the final analysis. Patients without diabetes mellitus served as controls (Group 1, n=150). Patients with diabetes mellitus were stratified into Group 2 (without SGLT2 inhibitors, n=50) and Group 3 (with SGLT2 inhibitors, n=50). Outcomes included postoperative urinary tract infections, bleeding-related complications, bladder tamponade, and postdischarge re-presentations within 30 days. Multivariate logistic regression analyses were adjusted for age, body mass index, age-adjusted Charlson Comorbidity Index, and duration of postoperative indwelling catheterization. RESULTS: Group 3 had a significantly longer hospital stay (p=0.003) and longer postoperative catheterization duration (p=0.009). Overall complications and bladder tamponade occurred more frequently in Group 3 (p=0.003 and p<0.01), but there were no significant differences regarding the need for surgical revision. Rates of postoperative urinary tract infections did not differ between groups. Postdischarge bladder tamponade was more frequent in Group 3 (p=0.03). In multivariate analyses, SGLT2 inhibitor therapy was independently associated with bleeding-related outcomes, while postoperative catheterization duration was associated with inpatient complications, inpatient bladder tamponade, and inpatient urinary tract infection. CONCLUSIONS: Perioperative SGLT2 inhibitor therapy was not associated with increased infectious complications after TUR-P or HoLEP. An association with bleeding-related events was observed, but these findings should be interpreted cautiously given the retrospective design, limited event numbers, and wide confidence intervals in some adjusted analyses. These results support further investigation and individualized perioperative assessment of SGLT2 inhibitor therapy.